NewLimit
PrivateLast Round
Series C
Jun 2, 2026
Est. Valuation
$3.1B
Total Funding Raised
$760M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
NewLimit is a biotechnology company that develops epigenetic reprogramming therapies to reverse the aging process and extend human healthspan.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NewLimit Comparables
Compare NewLimit with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Retro Biosciences | 88% | |
| Altos Labs | 86% | |
| Life Biosciences | 80% |
For institutional investors. Book with your work email.
NewLimit Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 2, 2026 | ||||
| Convertible Debt | Oct 20, 2025 | ||||
| Series B | May 6, 2025 | ||||
| Series A | May 16, 2023 |
For institutional investors. Book with your work email.
NewLimit Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Convertible Debt, Series C, Series B |
| S32 | Convertible Debt |
| Duke University Management Company | Convertible Debt |
| Greenoaks Capital Partners | Series C |
| Khosla Ventures | Series C, Series B |
| Founders Fund | Series B, Series C, Series A |
| Thrive Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 19, 2026
Grew 16% QoQ, from 55 to 64 employees.
- Aug 15, 2026
Grew 21% QoQ, from 52 to 63 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 16, 2026
NewLimit receives $110M in founder capital from its co-founders.
- recognized_asSep 25, 2026
Endpoints names NewLimit an Endpoints 11 2026 winner in California as it pursues a new class of anti-aging drugs.
For institutional investors. Book with your work email.
NewLimit Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NewLimit's valuation, stock price, and market status.
Is NewLimit a public or private company?
NewLimit is a private company.
What is the current stock price of NewLimit?
NewLimit is a private company, so its shares have no public market price. Caplight tracks NewLimit's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NewLimit worth (valuation)?
NewLimit's valuation is estimated at $3.1B based on funding round data.
Can I buy NewLimit stock?
NewLimit shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NewLimit's last funding round?
NewLimit's most recent funding round was Series C on June 2, 2026.
Who are the main investors in NewLimit?
Key investors in NewLimit include Founders Fund, Kleiner Perkins, Dimension Capital.
Will NewLimit IPO soon?
No public IPO plans have been announced for NewLimit.
How can I track NewLimit secondary market activity?
Caplight tracks bids, offers, and trades in NewLimit's shares on secondary markets.